中文

Journal of Shanghai University >

2018 , Vol. 24 >Issue 3: 336 - 340

DOI: https://doi.org/10.12066/j.issn.1007-2861.2002

Precision and Translational Medicine

Interpretation of Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases

Expand
  • Department of Gastroenterology, Tongji Hospital of Tongji University, Shanghai 200065, China

Received date: 2018-02-26

  Online published: 2018-06-27

Fold

Abstract

Hemorrhage resulting from high pressure of portal vein is a common complication of decompensated liver cirrhosis. Because of different courses, anatomic locations of varicose vein and complications, patients with cirrhosis need to be prudent in their choice of methods for diagnosis, treatment and prevention of rebleeding. Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases, which is based on a great deal of clinical data, may serve as a guideline for clinical practice in China as well. This paper, through close reading of the practice guidance, and through comparative analysis between the American guidance and that in China, hopes to shed some new light for medical practitioners on the handling of various problems connected with liver diseases.

Key words： cirrhosis; varicose bleeding; diagnosis; treatment

Cite this article

SONG Weiping, YANG Changqing . Interpretation of Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Journal of Shanghai University, 2018 , 24(3) : 336 -340 . DOI: 10.12066/j.issn.1007-2861.2002

References

[1] Groszmann R J, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med, 2005,353(21):2254-2261.
[2] De Franchis R, Faculty B V. Expanding consensus in portal hypertension: report of the Baveno VI Consensus workshop: stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015,63(3):743-752.
[3] 徐小元, 丁惠国, 贾继东, 等. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016,32(2):203-208.
[4] Damico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review[J]. Hepatology, 1995,22(1):332-354.
[5] Bhardwaj A, Kedarisetty C K, Vashishtha C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial[J]. Gut, 2017,66(10):1838-1843.
[6] Sarin S K, Mishra S R, Sharma P, et al. Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial[J]. Hepatol Int, 2013,7(1):248-256.
[7] Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding[J]. N Engl J Med, 2013,368(1):11-21.
[8] Wells M, Chande N, Adams P, et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds[J]. Aliment Pharmacol Ther, 2012,35(11):1267-1278.
[9] Seo Y S, Park S Y, Kim M Y, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage[J]. Hepatology, 2014,60(3):954-963.
[10] Puente A, Hernández-Gea V, Graupera I, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review[J]. Liver Int, 2014,34(6):823-833.
[11] Mishra S R, Sharma B C, Kumar A, et al. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial[J]. J Hepatol, 2011,54(6):1161-1167.
[12] El Amin H. A randomized trial of endoscopic variceal ligation versus cyanoacrylate injection for treatment of bleeding junctional varices[J]. Trop Gastroenterol, 2010,31(4):279-284.
[13] Caldwell S. Gastric varices: is there a role for endoscopic cyanoacrylates, or are we entering the BRTO era?[J]. Am J Gastroenterol, 2012,107(12):1784-1790.
[14] Mishra S R, Sharma B C, Kumar A, et al. Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial[J]. Gut, 2010,59(6):729-735.
[15] Hung H H, Chang C J, Hou M C, et al. Efficacy of non-selective beta-blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: a randomized controlled trial[J]. J Hepatol, 2012,56(5):1025-1032.
[16] Leithead J A, Rajoriya N, Tehami N, et al. Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation[J]. Gut, 2015,64(7):1111-1119.
Options
Outlines

/

〈 〉